Argenx

  1. Home
  2. Wiki

Argenx
Headquarters
Ghent Edit this on Wikidata
,
Belgium Edit this on Wikidata
Key people
Revenue2,143,000,000 euro (2024) Edit this on Wikidata
792,700,000 euro (2024) Edit this on Wikidata
Websiteargenx.com

Argenx SE (Euronext: ARGX) is a Dutch biopharmaceutical company.

The company has been a member of the EURO STOXX 50 since 22 September 2025.[2]

Products

[edit]

In April 2025, the US FDA approved a prefilled syringe version of the company's immune disorder drug Vyvgart.[3]

References

[edit]
  1. ^ "Management Team". Argenx. Retrieved 18 November 2025.
  2. ^ "Euro Stoxx 50 Adds Deutsche Bank, Siemens Energy, Argenx". Morningstar. 2 September 2025. Retrieved 18 November 2025.
  3. ^ "US FDA approves syringe version of Argenx's immune disorder drug". Reuters. Archived from the original on 13 April 2025. Retrieved 18 November 2025.